■ MATERIAL WEAKNESS WATCH
Nasdaq · CIK 0001808898

BNTC Benitec Biopharma Inc.

B
75 / 100
Material weaknesses
1
Restatements
0
Auditor changes
1
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
40
Remediation credit
15

Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.

Disclosures, in the company's words

  • Material weakness8-K · filed 2026-09-24 · Item 4.01source filing ↗
    “the material weakness in the Company s internal control over financial reporting, as reported in Item 9A of Part II of the Company s Annual Report on Form 10-K for the year ended June 30, 2025, filed with the U.S Securities and Exchange Commission ( SEC ) on September 22, 2025, related to inadequate design and implementation of controls over share-based compensation calculation review process.”
  • Auditor change with disagreements8-K · filed 2026-09-24 · Item 4.01source filing ↗
    “(ii) no reportable events, as such term is defined in Item 304(a)(1)(v) of Regulation S-K, except for the material weakness in the Company s internal control over financial reporting, as reported in Item 9A of Part II of the Company s Annual Report on Form 10-K for the year ended June 30, 2025”

Remediation disclosed

  • 8-K · filed 2026-09-24 · source filing ↗
    “The Company remediated the material weakness as of June 30, 2026, as reported in Item 9A of Part II of the Company s Annual Report on Form 10-K for the year ended June 30, 2026, filed with the SEC on September 14, 2026.”

Filings read

Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.